title: Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy.
abstract: OBJECTIVE
  To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period.
  
  
  RESULTS
  Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened.
  
  
  CONCLUSIONS
  Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.
authors.affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.
authors.forename: Seong-Woo
authors.initials: SW
authors.lastname: Kim
authors.forename: Myung Jin
authors.initials: MJ
authors.lastname: Kim
authors.forename: Kuhl
authors.initials: K
authors.lastname: Huh
authors.forename: Jaeryung
authors.initials: J
authors.lastname: Oh
mesh_terms: D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004359:Drug Therapy, Combination; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D008175:Lung Neoplasms / Q000473:pathology; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D012074:Remission Induction; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride